The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
James RubensteinJames L. Rubenstein, University of California, San Francisco, US, provides the Lymphoma Hub with his expert opinion on the role of autologous stem cell transplantation (ASCT) in treating primary central nervous system (CNS) lymphoma.
This video addresses a key question within the field; what is the optimal consolidation strategy following induction? The consensus strategy currently, following methotrexate-based induction, is whole-brain radiotherapy. However, there is increasing recognition of neurotoxicity and insufficient long term survival. Two major randomized phase II trials have now been completed which evaluated high dose chemotherapy and ASCT as consolidation. James L Rubenstein discusses both of these, concluding ASCT is superior in relation to event-free survival and neuro-cognitive endpoints. Another issue addressed by James L Rubenstein is the aging population, who are not ideal candidates for whole-brain radiation or ASCT. In this population, low dose lenalidomide maintenance has been shown to penetrate the CSF, is tolerable and patients have achieved long-term remissions in a phase I trial.
Consolidation strategies for CNS lymphoma